Certificate of Mailing 37 C.F.R. §1.8(a)

hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to MAIL STOP AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Name of Person Signing Certificate:

tober 28, 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First Named Inventor: Kyl L. Smith

Conf. No.:

2543

Group Art Unit: 1654

Appln. No.:

10/519,515

Examiner:

Not Yet Assigned

Filing Date:

December 7, 2004.

§ Attorney Docket No.: 681132-2US

Title: COMPOSITIONS FOR IMPROVING METAL PERFORMANCE

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97(b)

Enclosed is an Information Disclosure Citation Form PTO/SB/08A and/or 08B in accordance with 37 C.F.R. § 1.98(a)(1) and (a)(2) listing all patents, publications, applications, and/or other information being submitted for consideration which may be material to the patentability of this application and/or for which there may be a duty to disclose in accordance with 37 C.F.R. § 1.56. Also enclosed are copies of each of the foreign patents and/or non-patent literature documents cited therein but not copies of any U.S. patents and/or U.S. patent application publications in accordance with 37 C.F.R. § 1.98(a)(2). However, we will provide copies upon request.

The filing of this Information Disclosure Statement shall not be construed as an admission that any of the listed documents constitutes prior art, nor as an admission against interest in any manner.

No fee is believed to be due in connection with the filing of this Information Disclosure Statement since it is being filed before the mailing date of the first Office Action on the merits. However, the Commissioner is hereby authorized to charge any deficiencies or credit any overpayments to Deposit Account No. 50-1017.

It is respectfully requested that this Information Disclosure Statement and the documents listed on the attached Form PTO/SB/08A and/or 08B be considered and acknowledged by the Examiner in connection with the above-identified patent application, be made of record therein, and that the listed document(s) be cited in the issued patent.

Respectfully submitted,

Kyl L. Smith

Aaron R. Ettelman Attorney for Applicant Registration No. 42,516 Direct Dial: 215-965-1240

E-Mail: aettelman@akingump.com

Akin Gump Strauss Hauer & Feld LLP One Commerce Square 2005 Market Street, Suite 2200 Philadelphia, PA 19103

Telephone No.: 215-965-1200

Fax No.: 215-965-1210

ARE:rc Enclosures

				()(1 11	<u> </u>	
Form PTC	•		3			Complete if Known
.1:			X	التال شيسية الأ	polication Number	10/519,515
INFORMATION DISCLOSURE				SURTERIOR	Filing Date	December 7, 2004
STATE	ME	NT B	APPLI	CANT	First Named Inventor	Kyl L. Smith
(,,,,,,			-4		Group Art Unit	1654
(use as many sheets as necessary)			ets as nec	essary)	Examiner Name Not Yet Assigned	
Sheet	1	•	of	29	Attorney Docket Number	681132-2US

	U.S. PATENT DOCUMENTS							
Exr Initials	U.S. Patent Document Number	Kind Code (if known)	Name of First Inventor of Cited Document	Date of Publication of Cited Document MM-YYYY				

FOREIGN PATENT DOCUMENTS								
Exr Initials	Country Code	Foreign Patent Docume Number	Kind Code (if known)	Name of Applicant of Cited Document	Date of Publication of Cited Document MM-YYYY	T ₁		

	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Exr Initials	Include Name of first Author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), volume-issue number(s), page(s), date (in parentheses). If a book, also include publisher and city and/or county where published.	T ₁
	CENACCHI T, BERTOLDIN T, FARINA C, FIORI MG, CREPALDI G. "Cognitive	
	decline in the elderly: A double blind, placebo-controlled multicenter study on efficacy of	
	phosphatidylserine administration." Aging Clin Exp Res, 5:123-133 (1993).	
	CROOK TH, TINKLENBERG J, YESAVAGE J, PETRIE W, NUNZI MG, MASSARI	
	DC. "Effects of phosphatidylserine in age-associated memory impairment." Neurology,	
	41:644-649 (1991).	
	AMADUCCI L, CROOK TH, LIPPI A, BRACCO L, BALDERESCHI M,	
	LATORRACA S, PIERSANTI P, TESCO G, SORBI S. "Use of phosphatidylserine in	
	Alzheimer's disease." Annals NYAcadSci, 640:245-249 (1991).	
	CROOK T, PETRIE W, WELLS C, MASSARI DC. "Effects of phosphatidylserine in	
	Alzheimer's disease." Psychopharmacol Bull, 28:61-66 (1992).	
	TOFFANO G, BATTISTELLA A, ORLANDO P. "Pharmacokinetics of radiolabelled brain	
	phosphatidylserine." Clin Trials J, 24:18-24 (1987).	
	NISHIZUKAY. "Turnover of inositol phospholipids and signal transduction." Science,	
	225:1365-1370 (1984).	
-	COHEN SA, MULLER WE. "Age-related alterations of NMDA-receptor properties in the mouse	
	forebrain: Partial restoration by chronic phosphatidylserine treatment." Brain Res, 584:174-180	
	(1992).	
	BALL MJ. "Neuronal loss, neurofibrillary tangles and granulovacuolar degeneration in the	
	hippocampus with ageing and dementia. A quantitative study." Ada Neuropath, 37:111-118	
_	(1977).	
····	SCHEIBEL ME, LINDSAY RD, TOMIYASU U, SCHEIBEL AB. "Progressive dendritic	
	changes in the aging human limbic system." Exptl Neurol, 53:420-430 (1976).	
	LIPPAAS, CRITCHETTDJ, EHLERTF, YAMAMURAHI, ENNASJ, BARTUSRT. "Age-	
	related alterations in neurotransmitter receptors: An electrophysiological and biochemical	
	analysis." Neurobiol Aging, 2:3-8.(1981).	

Examiner	Date	
Signature	 Considered	

Form PT	O/SB/08A			Complete if Known		
	` 			Application Number	10/529,515	
	MATION			Filing Date	December 7, 2004	
STATE	MENT B	Y APPLI	CANT	First Named Inventor	Kyl L. Smith	
				Group Art Unit	1654	
(use a	(use as many sheets as necessary)			Examiner Name	Not Yet Assigned	
Sheet	2	of	29	Attorney Docket Number	681132-2US	

U.S. PATENT DOCUMENTS							
Exr Initials	U.S. Patent Document		Name of First Inventor of Cited Document	Date of Publication of			
	Number	Kind Code (if known)		Cited Document MM-YYYY			

FOREIGN PATENT DOCUMENTS								
Exr Initials	Country Code	Foreign Patent Docum Number	Kind Code (if known)	Name of Applicant of Cited Document	Date of Publication of Cited Document MM-YYYY	T ₁		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Include Name of first Author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), volume-issue number(s), page(s), date (in parentheses). If a book, also include publisher and city and/or county where published.	T ₁
PEPEU G, SPIGNOLI G. "Nootropic drugs and brain cholinergic mechanisms." Prog Neuro-	ļ
Psychopharmacol Biol Psychiat, 13:S77-S88 (1989).	
BARTUS RT, DEAN RL, BEER B, LIPPA AS. "The cholinergic hypothesis of geriatric memory	
TANGLOS EG, BOEVE BF, KOKMEN E. "Memory and MRI-based hippocampal volumes in aging and AD." <i>Neuro</i> ,54:581-587 (2000).	
CORWIN J, DEAN RL, BARTUS RT, ROTROSEN J, WATKINS DL. "Behavioral effects	
of phosphatidylserine in the aged Fischer 344 rat: Amelioration of passive avoidance deficits	
without changes in psychomotor task performance." Neurobiol	
ZANOTTI A, APORTI F, TOFFANO G, VALZELLI L. Effects of phosphatidylserine on	
avoidance relearning in rats. Pharmacol Res Commun, 16:485-493 (1984).	
DRAGO F, CANONICO PL, SCAPAGNINI U. "Behavioral effects of phosphatidylserine in aged	
rats." Neurobiol Aging 2:209-213 (1981).	
APORTI F, BORSATO R, CALDERINI G, RUBINI R, TOFFANO G, ZANOTTI A, VALZELLI	
L, GOLDSTEIN L. "Age-dependent spontaneous EEG bursts in rats: Effects of brain	
phosphatidylserine." Neurobiol Aging, 7:115-120 (1986).	
CASAMENTI F, MANTOVANI P, AMADUCCI L, PEPEU G. "Effect of phosphatidylserine on	
·	
	magazine, journal, serial, symposium, catalog, etc.), volume-issue number(s), page(s), date (in parentheses). If a book, also include publisher and city and/or county where published. PEPEU G, SPIGNOLI G. "Nootropic drugs and brain cholinergic mechanisms." <i>Prog Neuro-Psychopharmacol Biol Psychiat</i> , 13:S77-S88 (1989). BARTUS RT, DEAN RL, BEER B, LIPPA AS. "The cholinergic hypothesis of geriatric memory dysfunction." <i>Science</i> , 217:408-417 (1982). PETERSEN RC, JACK CR, JR, XU YC, WARING SC, O'BRIEN PC, SMITH GE, IVNIK RJ, TANGLOS EG, BOEVE BF, KOKMEN E. "Memory and MRI-based hippocampal volumes in aging and AD." <i>Neuro</i> , 54:581-587 (2000). CORWIN J, DEAN RL, BARTUS RT, ROTROSEN J, WATKINS DL. "Behavioral effects of phosphatidylserine in the aged Fischer 344 rat: Amelioration of passive avoidance deficits without changes in psychomotor task performance." <i>Neurobiol</i> ZANOTTI A, APORTI F, TOFFANO G, VALZELLI L. Effects of phosphatidylserine on avoidance relearning in rats. <i>Pharmacol Res Commun</i> , 16:485-493 (1984). DRAGO F, CANONICO PL, SCAPAGNINI U. "Behavioral effects of phosphatidylserine in aged rats." <i>Neurobiol Aging</i> 2:209-213 (1981). APORTI F, BORSATO R, CALDERINI G, RUBINI R, TOFFANO G, ZANOTTI A, VALZELLI L, GOLDSTEIN L. "Age-dependent spontaneous EEG bursts in rats: Effects of brain phosphatidylserine." <i>Neurobiol Aging</i> , 7:115-120 (1986). ZANOTTI A, VALZELLI L, TOFFANO G. "Chronic phosphatidylserine treatment improves spatial memory and passive avoidance in aged rats." <i>Psychopharmacol</i> , 99:316-321 (1989).

Examiner	Date	
Signature	Considered	

Form PT	O/SB/08A			Complete if Known		
l <u>-</u>				Application Number	10/519,515	
	MATION			Filing Date	December 7, 2004	
STATE	MENT B	Y APPLIC	CANT	First Named Inventor	Kyl L. Smith	
(1100.0	(Group Art Unit	1654	
(use as many sheets as necessary)			essary)	Examiner Name	Not Yet Assigned	
Sheet	3	of	29	Attorney Docket Number	681132-2US	

U.S. PATENT DOCUMENTS							
Exr Initials	U.S. Patent Document		Name of First Inventor of Cited Document	Date of Publication of			
	Number	Kind Code (if known)		Cited Document MM-YYYY			

	FOREIGN PATENT DOCUMENTS							
		Foreign Patent Docume	ent		Date of	Τı		
Exr Initials	Country	Number	Kind Code	Name of Applicant of Cited Document	Publication of			
	Code		(if known)		Cited Document			
		,			MM-YYYY	 _		
						İ		

	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Exr Initials	Include Name of first Author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), volume-issue number(s), page(s), date (in parentheses). If a book, also include publisher and city and/or county where published.	T ₁
	NUNZI MG, MILAN F, GUIDOLIN D, POLATO P, TOFFANO G. "Effects of	
	phosphatidylserine administration on age-related structural changes in the rat hippocampus and septal complex." <i>Pharmacopsychiat</i> , 22:125-128 (1989).	
	HEISS W-D, SZELIES B, KESSLER J, HERHOLZ K. "Abnormalities of energy metabolism in	
	Alzheimer's disease studied with PET." Annals NYAcad Sci, 640:65-71 (1991).	
	VILLARDITA C, GRIOLI S, SALMERI G. NICOLETTI F, PENNISI G. "Multicentre clinical	
	trial of brain phosphatidylserine in elderly patients with intellectual deterioration." <i>Clin Trials J</i> , 4:84-93 (1987).	
	PALMIERI G, PALMIERI R, INZOLI MR, LOMBARDI G, SOTTINI C, TAVOLATO B,	
	GIOMETTO B. "Double-blind controlled trial of phosphatidylserine in patients with senile	
	mental deterioration." Clin Trials J, 24:73-83 (1987).	
	AMADUCCI L. "Phosphatidylserine in the treatment of Alzheimer's disease: Results of a	
	multicenter study." Psychopharmacol Bull, 24:130-134 (1988).	
	DELWAIDE PJ, GYSERYNCK-MAMBOURG AM, HURLET A, YLIEFF M. "Double-blind randomized controlled study of phosphatidylserine in senile demented patients." <i>Acta Neurol Scand</i> , 73:136-140 (1986).	
	ENGEL RR. "Double-blind cross-over study of phosphatidylserine vs. placebo in subjects with early cognitive deterioration of the Alzheimer type." <i>Eur Neuropsychopharmacol</i> , 2:149-155 (1992).	
	SCHREIBER S, KAMPF-SHERF O, GORFINE M, KELLY D, OPPENHEIM Y, LERER B. "An open trial of plant-source derived phosphatidylserine for treatment of age-related cognitive decline." <i>Isr J Psychiatry Relat Sci</i> , 37:302-307 (2000).	
	MAGGIONI M, PICOTTI GB, BONDIOLOTTI GP, PANERAI A, CENACCHI T, NOBILE P, BRAMBILLA F. "Effects of phosphatidylserine therapy in geriatric patients with depressive disorders." <i>Acta Psychiatr Scand</i> , 81:265-270 (1990).	

Examiner	Date
Signature	Considered

Form PT	O/SB/08A	\		Complete if Known		
l	INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Application Number	10/519,515	
				Filing Date	December 7, 2004	
STATE				First Named Inventor	Kyl L. Smith	
(1100.0				Group Art Unit	1654	
(use a	(use as many sheets as necessary)		Examiner Name	Not Yet Assigned		
Sheet 4 of 29		Attorney Docket Number	681132-2US			

U.S. PATENT DOCUMENTS							
Exr Initials	U.S. Patent Document Number	Kind Code (if known)	Name of First Inventor of Cited Document	Date of Publication of Cited Document MM-YYYY			

			FOREIGN PATE	NT DOCUMENTS		
Exr Initials	Country Code	Foreign Patent Docun Number	Nent Kind Code (if known)	Name of Applicant of Cited Document	Date of Publication of Cited Document MM-YYYY	T ₁

- 49,0	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	•
Exr Initials	Include Name of first Author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), volume-issue number(s), page(s), date (in parentheses). If a book, also include publisher and city and/or county where published.	T,
	CENACCHI T, BAGGIO C, PALIN E. "Human tolerability of oral phosphatidylserine assessed through laboratory examinations." <i>Clin Trials J</i> , 24:125-131 (1987).	
	HEISS WD. "Long-term effects of phosphatidylserine, pyritinol, and cognitive training in Alzheimer's disease." <i>Cognitive Deterioration</i> , 5:88-98 (1994).	
	SINFORIANI E, AGOSTINIS C, MERLO P, GUALTIERI S, MAURI M, MANCUSO A.	
	"Cognitive decline in ageing brain. Therapeutic approach with phosphatidylserine." Clin Trials Jim, 24:115-125.	
	GRANATA Q, DIMICHELE J. "Phosphatidylserine in elderly patients. An open trial." Clin Trials J, 24:99-103 (1987).	
	ALLEGRO L, FAVARETTO V, ZILIOTTO G. "Oral phosphatidylserine in elderly patients with cognitive deterioration. An open study." <i>Clin Trials J</i> , 24:104-108 (1987).	
	CAFFARA P, SANTAMARIA V. "The effects of phosphatidylserine in patients with mild cognitive decline. An open trial." <i>Clin</i> 7Wa/s./, 24:109-1 14 (1987).	
	ROSADINI G, SANNITA WG, NOBILI F, CENACCHI T. "Phosphatidylserine: Quantitative EEG effects in healthy volunteers." <i>Neuropsychobiol</i> , 24:42-48 (1990-1991).	
	HEISS W-D, KESSLER J, SLANSKY I, MIELKE R, SZELIES B, HERHOLZ K. "Activation PET as an instrument to determine therapeutic efficacy in Alzheimer's disease." <i>Annals NYAcad Sci</i> , 695:327-331 (1993).	
	FILBURN CR. "Dietary supplementation with phospholipids and docosahexaenoic acid for agerelated cognitive impairment." <i>J Am Nutraceutical Assoc</i> , 3:45-55 (2000).	

Examiner	Date	
Signature	Considered	

Form PT	O/SB/08A			Complete if Known		
				Application Number	10/519,515	
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Filing Date	December 7, 2004	
STATE				First Named Inventor	Kyl L. Smith	
/				Group Art Unit	1654	
(use a				Examiner Name	Not Yet Assigned	
Sheet 5 of 29		Attorney Docket Number	681132-2US			

	U.S. PATENT DOCUMENTS							
Exr Initials	U.S. Patent Document		Name of First Inventor of Cited Document	Date of Publication of				
	Number	Kind Code (if known)		Cited Document MM-YYYY				

	FOREIGN PATENT DOCUMENTS							
Exr Initials	Country Code	Foreign Patent Documen Number	t Kind Code (if known)	Name of Applicant of Cited Document	Date of Publication of Cited Document MM-YYYY	T ₁		

	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Exr Initials	Include Name of first Author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), volume-issue number(s), page(s), date (in parentheses). If a book, also include publisher and city and/or county where published.	T ₁
1	PEVET P, BUIJS RM, MASSON-PEVET M. "Effect of pinealectomy and a constant high level	
	of circulating melatonin or of 5-methoxytryptamine on the vasopressinergic innervation in the	
	brain of the European hamster (Cricetus cricetus, L)." J Neural Transm, 70:287-294 (1987).	
	KLINKHAMMER P, SZELIES, HEISS W-D. "Effect of phosphatidylserine on cerebral glucose	
	metabolism in Alzheimer's disease." Dementia, 1:197-201 (1990).	
	LATORRACA S, PIERSANTI P, RESCO G, PIACENTINI S, AMADUCCI L, SORBI S.	
	"Effect of phosphatidylserine on free radical susceptibility in human diploid fibroblasts." J Neural	
	Transm, 6:73-77 (1993).	
	COLODNY L, HOFFINAN RL. "Inositol - clinical applications for exogenous use." <i>Alternative MedRev</i> , 3:432-447 (1998).	
	BARKAI AI, DUNNER DL, GROSS HA, MAYO P, FIEVE RR. "Reduced myo-inositol levels	
	in cerebrospinal fluid from patients with affective disorder." Biol Psychiatry, 13:65-72 (1978).	
	LEVINE J, BARAK Y, GONZALVES M, SZOR H, ELIZUR A, KOFMAN O, BELMAKER	
	RH. "Double-blind, controlled trial of inositol treatment of depression." Am J Psychiatry,	
	152:792-794 (1995).	<u> </u>
	LEVINE J, BARAK Y, KOFMAN O, BELMAKER RH. "Follow-up and relapse analysis of an	
	inositol study of depression." Isr J Psychiatry Relat Sci, 32:14-21 (1995).	
	BENJAMIN J, LEVINE J, FUX M, AVIV A, LEVY D, BELMAKER RH. "Double-blind,	
	placebo-controlled, crossover trial of inositol treatment for panic disorder." Am J Psychiatry,	
	152:1084-1086 (1995).	

Examiner	Date	
Signature	Considered	

Form PT	O/SB/08/	4			Complete if Known	
· · · · · · · · · · · · · · · · · · ·				Application Number	10/519,515	
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Filing Date	December 7, 2004	
STATE				First Named Inventor	Kyl L. Smith	
<i>(</i>				Group Art Unit	1654	_
(use a	(use as many sheets as necessary)		ecessary)	Examiner Name	Not Yet Assigned	
Sheet	6	of	29	Attorney Docket Number	681132-2US	

	U.S. PATENT DOCUMENTS								
Exr Initials	U.S. Patent Document		Name of First Inventor of Cited Document	Date of Publication of					
	Number	Kind Code (if		Cited Document					
		known)		MM-YYYY					

FOREIGN PATENT DOCUMENTS								
Exr Initials	Country Code	Foreign Patent Docun Number	nent Kind Code (if known)	Name of Applicant of Cited Document	Date of Publication of Cited Document MM-YYYY	T ₁		

	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Exr Initials	Include Name of first Author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), volume-issue number(s), page(s), date (in parentheses). If a book, also include publisher and city and/or county where published.	T ₁
	IKEMOTO A, KOBAYASHI T, EMOTO K, UMEDA M, WATANABE S, OKUYAMA H.	
	"Effects of docosahexaenoic and arachidonic acids on the synthesis and distribution of	
_	aminophospholipids during neuronal differentiation of PC 12 cells." <i>Arch Biochem Biophys</i> , 364:67-74 (1999).	
	GREEN P, GLOZMAN S, KAMENSKY B, YAVIN E. "Developmental changes in rat brain	
0	membrane lipids and fatty acids: The preferential prenatal accumulation of docosahexaenoic acid." <i>JLipidRes</i> , 40:960-966 (1999).	
	STEVENS LJ, ZENTALL SS, DECK JL, ABATE ML, WATKINS BA, LIPP SR, BURGESS JR.	
	"Essential fatty acid metabolism in boys with attention-deficit hyperactivity disorder." Am J Clin	
	Nutr, 62:761-768 (1995).	
	STEVENS LJ, ZENTALL SS, ABATE ML, KUCZEK T, BURGESS JR. "Omega-3 fatty acids	
	in boys with behavior, learning, and health problems." Physiol Behav, 59:915-920 (1996).	
	JONES CR, ARAI T, RAPOPORT SI. "Evidence for the involvement of docosahexaenoic acid	
	in cholinergic stimulated signal transduction at the synapse." Neurochem Res, 22:663-670 (1997).	
	ITOKAZU N, IKEGAYA Y, NISHIKAWA M, MATSUKI N. "Bidirectional actions of	
	docosahexaenoic acid on hippocampal neurotransmissions in vivo." Brain Res, 862:211-216	
	(2000).	
	NISHIKAWA M, KIMURA S, AKAIKE N. "Facilitatory effect of docosahexaenoic acid on JV-	
	methyl-D-aspartate response in pyramidal neurons of rat cerebral cortex." J Physiol, 475:83-93	
	(1994).	
	POLING JS, VICINI S, ROGAWSKI MA, SALEM N, JR. "Docosahexaenoic acid block of	
	neuronal voltage-gated K+ channels: Subunit selective antagonism by zinc." Neuropharmacol,	
	35:969-982 (1996).	

Examiner	Date	
Signature	Considered	

Form PT	O/SB/08A			Complete if Known				
 				Application Number	10/519,515			
	INFORMATION DISCLOSURE			Filing Date	December 7, 2004			
STATE	MENT B	Y APPL	ICANT	First Named Inventor	Kyl L. Smith			
(Group Art Unit	1654			
(use a	(use as many sheets as necessary)		ecessary)	Examiner Name	Not Yet Assigned			
Sheet	7	of	29	Attorney Docket Number	681132-2US			

U.S. PATENT DOCUMENTS							
Exr Initials	U.S. Patent Document		Name of First Inventor of Cited Document	Date of Publication of			
	Number	Kind Code (if known)		Cited Document MM-YYYY			
<u></u>							

	FOREIGN PATENT DOCUMENTS								
Exr Initials	Country Code	Foreign Patent Documen Number	Kind Code (if known)	Name of Applicant of Cited Document	Date of Publication of Cited Document MM-YYYY	T ₁			

	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Exr Initials	Include Name of first Author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), volume-issue number(s), page(s), date (in parentheses). If a book, also include publisher and city and/or county where published.	T ₁
	SIMOPOULOS A. "Omega-3 fatty acids in health and disease and in growth and development." <i>AmJ Clin Nutr</i> 191, 54:438-463.	
	DELION S, CHALON S, GUILLOTEAU D, LEJEUNE B, BESNARD J-C, DURAND G. "Age-	
	related changes in phospholipids fatty acid composition and monoaminergic neurotransmission in	
	the hippocampus of rats fed a balanced or an n-3 poryunsaturated fatty acid-deficient diet."	
	JLipidRes, 38:680-689 (1997).	
	YOUDIM KA, MARTIN A, JOSEPH JA. "Essential fatty acids and the brain: Possible	
	health implications." IntJDevl Neurosci, 18:383-399 (2000).	
	ADAMS PB, LAWSON S, SANIGORSKI A, SINCLAIR AJ. "Arachidonic to	
	eicosapentaenoic acid ratio in blood correlates positively with clinical symptoms of	
	depression." <i>Lipids</i> , 31 :S 167-S176 (1996).	
	KALMIJN S, FESKENS EJM LAUNER LJ, KROMHOUT D. "Polyunsaturated fatty	
	acids, antioxidants, and cognitive function in very old men." Am J Epidemiol, 145:33-41	
	(1997).	
	NEWMAN PE. "Could diet be one of the causal factors of Alzheimer's disease?" Med	
	Hypotheses, 39:123-126 (1992).	
	OKADA M, AMAMOTO T, TOMONAGA M, KAWACHI A, YAZAWA K, MINE K,	
	FUJIWARA M. "The chronic administration of docosahexaenoic acid reduces the spatial	
	cognitive deficit following transient forebrain ischemia in rats." <i>Neurosci</i> , 71:17-25 (1996).	
	SHIKANO M, MASIZAWA Y, YAZAWA K. "Effect of docosahexaenoic acid on the	
	generation of platelet-activating factor by eosinophilic leukemia cells, Eol-1." J Immunol,	
	150:3525-3533 (1993).	

Examiner	Date	
Signature	Considered	

Form PT	D/SB/08A				Complete if Known	
l				Application Number	10/519,515	
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Filing Date	December 7, 2004	
STATE				First Named Inventor	Kyl L. Smith	
(1100.0				Group Art Unit	1654	
(use a	(use as many sheets as necessary)		Examiner Name	Not Yet Assigned		
Sheet	8	of	29	Attorney Docket Number	681132-2US	

	U.S. PATENT DOCUMENTS							
Exr Initials	U.S. Patent Document		Name of First Inventor of Cited Document	Date of Publication of				
	Number	Kind Code (if known)		Cited Document MM-YYYY				

			FOREIGN PATE	NT DOCUMENTS		
Exr Initials	Country Code	Foreign Patent Docum Number	Kind Code (if known)	Name of Applicant of Cited Document	Date of Publication of Cited Document MM-YYYY	T ₁

	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Exr Initials	Include Name of first Author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), volume-issue number(s), page(s), date (in parentheses). If a book, also include publisher and city and/or county where published.	T ₁
	CORNFORD EM, BRAUN LD, OLDENDORF WH. "Carrier mediated blood-brain barrier	
	transport of choline and certain choline analogs." J Neurochem, 30:299-308.	
	ZEISEL SH, DA COSTA K-A, FRANKJIN PD, ALEXANDER EA, LAMONT JT, SHEARD	
	NF, BEISER A. CHOLINE, "An essential nutrient for humans." FASEB J, 5:2093-2098 (1991).	
	WURTMAN RJ, HIRSCH MJ, GROWDON JH. "Lecithin consumption raises serum-	
	free- choline levels." Lancet, 2M-69 (1977)	
	BLUSZTAJN JK, WURTMAN RJ. "Choline and cholinergic neurons." Science,	
	221:614:620 (1983).	
	DAVIS KL, MOHS RC, TINKLENBERG JR, HOLLISTER LE, PFEFFERBAUM A,	
	KOPELL BS. "Cholinomimetics and memory. The effect of choline chloride." Arch	
	Neurol, 37:49-52 (1980).	
	MOHS RC, DAVIS KL, TINKLENBERG JR, HOLLISTER LE. "Choline chloride	
	effects on memory in the elderly." Neurobiol Aging, 1:21-25 (1981).	
	BUCHMN AL, SOHEL M, BROWN M, JENDEN DJ, AHN C, ROCH M, BRAWLEY	
	TL. "Verbal and visual memory improve after choline supplementation in long-term total	
	parenteral nutrition: A pilot study." JP£TV, 25:30-35 (2001).	
	SITARAM N, WEINGARTNER H, GILLIN JC. "Human serial learning: Enhancement	
	with arecholine and choline and impairment with scopolamine." Science, 210:274-276	
	(1978).	
	SITARAM N, WEINGARTNER H, CAINE ED, GILLIN JC. "Choline: Selective	
	enhancement of serial learning and encoding of low imagery words in man." Life Sci,	
	22:1555-1560 (1978).	
	SU T-Z, CAMPBELL GW, OXENDER DL. "Glutamine transport in cerebellar granule	
	cells in culture." Brain Res, 757:69-78 (1997).	

Examiner	Date
Signature	Considered

Form PT0	D/SB/08A				Complete if Known
				Application Number	10/519,515
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Filing Date	December 7, 2004
STATE				First Named Inventor	Kyl L. Smith
(Group Art Unit	1654
(use a	(use as many sheets as necessary)			Examiner Name	Not Yet Assigned
Sheet	Sheet 9 of 29		Attorney Docket Number	681132-2US	

	U.S. PATENT DOCUMENTS							
Exr Initials	U.S. Patent Document		Name of First Inventor of Cited Document	Date of Publication of				
	Number	Kind Code (if known)		Cited Document MM-YYYY				

			FOREIGN PATE	NT DOCUMENTS		
Exr Initials	Country Code	Foreign Patent Docum Number	Kind Code (if known)	Name of Applicant of Cited Document	Date of Publication of Cited Document MM-YYYY	T ₁

	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Exr Initials	Include Name of first Author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), volume-issue number(s), page(s), date (in parentheses). If a book, also include publisher and city and/or county where published.	T ₁
	POW DV, ROBINSON SR. "Glutamate in some retinal neurons is derived solely from glia." Neurosci, 60:355-366 (1994).	
	KAPETANOVIC IM, YONEKAWA WD, KUPFERBERG HJ. "Time-related loss of glutamine	
	from hippocampal slices and concomitant changes in neurotransmitter amino acids."	
	JNeurochem, 61:865-872 (1993).	
	NIIHARA Y, ZEREZ CR, AKIYAMA DS, TANAKA KR. "Oral L-glutamine therapy for sickle	
	cell anemia: 1. Subjective clinical improvement and favorable change in red cell NAD redox	
	potential." Am JHematol, 58:117-121 (1998).	
	GELLER SJ. "Comparison of a tranquilizer and a psychic energizer." JAMA, 174:481-484	
	(1960).	
	LEWIS JA, YOUNG R. "Deanol and methylphenidate in minimal brain dysfunction." Clin	
	Pharmacol Ther, 17:534-540 (1975).	
	ZS-NAGY I, FLOYD RA. "Electron spin resonance spectroscopic demonstration of the	
	hydroxyl free radical scavenger properties of dimethylaminoethanol in spin trapping	
	experiments confirming the molecular basis for the biological effects of centrophenoxine."	
	Arch Gerontol Geriatr, 3:297-310 (1984).	
	OETTINGER L. "The use of Deanol in the treatment of disorders of behavior in	
	children." JPediatr: 671-675.	
	FERRIS SH, SATHANANTHAN G, GERSHON S, CLARK C. "Senile dementia:	
	Treatment with Deanol." J Am Geriatr Soc, 25:241-244 (1977).	
	DIMPFEL W, HOFRNAN HC, PROHASKA A, SCHOBER F, SCHELLENBERG R.	
	"Source density analysis of functional topographical EEG: Monitoring of cognitive drug	
	action." Eur JMed Res, 1:283-290 (1995-1996).	
	VED HS, KOENIG ML, DAVE JR, DOCTOR BP. "Huperzine A, a potential therapeutic	
	agent for dementia, reduces neuronal cell death caused by glutamate." NeuroReport,	
	8:963-968 (1997).	

Examiner	Date
Signature	Considered

Form PT	O/SB/08A				Complete if Known
·	use as many sheets as necessary)		Application Number	10/519,515	
	FORMATION DISCLOSURE ATEMENT BY APPLICANT use as many sheets as necessary)		Filing Date	December 7, 2004	
STATE	STATEMENT BY APPLICANT		First Named Inventor	Kyl L. Smith	
(1100.0	e as many sheets as necessary)		Group Art Unit	1654	
(use a	(use as many sheets as necessary)			Examiner Name	Not Yet Assigned
Sheet	Sheet 10 of 29			Attorney Docket Number	681132-2US

	U.S. PATENT DOCUMENTS						
Exr Initials	U.S. Patent Document		Name of First Inventor of Cited Document	Date of Publication of			
	Number	Kind Code (if known)		Cited Document MM-YYYY			

			FOREIGN PATE	NT DOCUMENTS		
Exr Initials	Country Code	Foreign Patent Docume Number	ent Kind Code (if known)	Name of Applicant of Cited Document	Date of Publication of Cited Document	T₁
			(\)		MM-YYYY	

	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS						
Exr Initials	Include Name of first Author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), volume-issue number(s), page(s), date (in parentheses). If a book, also include publisher and city and/or county where published.	T ₁					
	CHENG DH, REN H, TANG X-C. "Huperaine A, a novel promising acetylcholinesterase inhibitor." <i>NeuroReport</i> , 8:97-101 (1996).						
	HANIN I, TANG X-C, KINDEL GL, KOZIKOWSKI AP. "Natural and synthetic						
	Huperzine A: Effect on cholinergic function in vitro and in vivo." Annals NYAcad Sci 695:304-306 (1993).						
	TANG X-C. "Huperzine A (Shuangyiping): promising drug for Alzheimer's research." <i>Ada Pharmacol Sinica</i> , 17:481-484 (1996).						
	XIONG ZQ, HAN YF, TANG X-C. "Huperzine A ameliorates the spatial working memory impairments induced by AF64A." <i>NeuroReport</i> , 6:2221-2224 (1995).						
	PERRY EK, TOMLINSON BE, BLESSED G, BERGMANN K, GIBSON PH, PERRY						
	RH. "Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia." <i>Br MedJ</i> , 2:1457-1459 (1978).						
	WILCOCK GK, ESIRI MM, BOWEN DM, SMITH CCT. "Alzheimer's disease.						
	Correlation of cortical choline acetyltransferase activity with the severity of dementia and histological abnormalities." <i>JNeurolSci</i> , 57:407-417 (1982).						
	THAI LJ, MASUR DM, BLAU AD, FULD PA, KLAUBER MR. "Chronic oral physostigmine without lecithin improves memory in Alzheimer's disease." <i>J Am GeriatrSoc</i> , 37:42-48 (1989).						
	SUMMERS WK, MAJOVSKI LV, MARSH GM, TACHIKI K, KLING A. "Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type." NewEnglJMed, 315:1241-1245 (1986).						
	XU S-S, CAI Z-Y, QU Z-W, YANG R-M, CAI Y-L, WANG G-Q, SU X-Q, ZHONG X-S, CHENG R-Y, XU W-A, LI J-X, FENG B. "Huperzine-A in capsules and tablets for treating						
	patients with Alzheimer's disease." Ada Pharmacol Sinica, ^0:486-490 (1999).						
	XU S-S, GAO Z-X, WENG Z, DU Z-M, XU W-A, YANG J-S, ZHANG M-L, TONG Z-H,						
	FANG Y-S, CHAI X-S, LI S-L. "Efficacy of tablet huperzine-A on memory, cognition, and						
	behavior in Alzheimer's disease." Ada Pharmacol Sinica, 16:391-395 (1995).						
Examir Signati							

Form PT	O/SB/08A			Complete if Known		
 				Application Number	10/519,515	
	MATION			Filing Date	December 7, 2004	
STATE	STATEMENT BY APPLICANT			First Named Inventor	Kyl L. Smith	
(1100.0	(use as many sheets as necessary)			Group Art Unit	1654	
(use a				Examiner Name	Not Yet Assigned	
Sheet	Sheet 11 of 29		Attorney Docket Number	681132-2US		

U.S. PATENT DOCUMENTS							
Exr Initials	U.S. Patent Document		Name of First Inventor of Cited Document	Date of Publication of			
	Number	Kind Code (if known)		Cited Document MM-YYYY			
	·						

	FOREIGN PATENT DOCUMENTS							
Exr Initials	Country Code	Foreign Patent Docume Number	Kind Code (if known)	Name of Applicant of Cited Document	Date of Publication of Cited Document MM-YYYY	T ₁		

	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS]
Exr Initials	Include Name of first Author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), volume-issue number(s), page(s), date (in parentheses). If a book, also include publisher and city and/or county where published.	T ₁
	SUN Q-Q, XU S-S, PAN J-L, GUO H-M, CAO W-Q. "Huperzine-A capsules enhance memory	
	and learning performance in 34 pairs of matched adolescent students." <i>Ada Pharmacol Sinica</i> , 20:601-603 (1999).	
	DRAGO F, VALERLO C, D'AGATA V, ASTUTO C, SPADARO F, CONTINELLA G,	
	SCAPAGNINI U. "Pyroglutamic acid improves learning and memory capacities in old rats." <i>Functional Neurol</i> , 3:137-143 (1988).	
	DRAGO F, CONTINELLA G, VALERIO C, D'AGATA V, ASTUTO C, SPADARO F, SCAPAGNINI U. "Effects of pyroglutamic acid on learning and memory processes of the rat." <i>Acta Therapeutica</i> , 13:587-594 (1987).	
	SPIGNOLI G, MAGNANI M, GIOVANNINI MG, PEPEU G. "Effect of pyroglutamic acid stereoisomers on ECS and scopolamine-induced memory disruption and brain acetylcholine levels in the rat." <i>Phamacol Res Commun</i> , 19:901-912 (1987).	
	GRIOLI S, LOMEO C, QUATTROPANI MC, SPIGNOLI G, VILLARDITA C. "Pyroglutamic acid improves the age associated memory impairment." <i>Fundam Clin Pharmacol</i> , 4:169-173 (1990).	
	SINGH HK, DHAWAN BN. "Neuropsychopharmacological effects of the Ayurvedic nootropic Bacopa monniera Linn. (Brahmi)." Indian J Pharmacol, 29:S359:S365 (1997).	
	MORGAN M, BONE K. "Brahmi (Bacopa) - revered Ayurvedic herb." <i>Modern Phytotherapist</i> , 5:21-27 (1999).	
	SINGH HK, DHAWAN BN. "Effect of <i>Bacopa monniera</i> Linn. { <i>Brahmi</i>) extract on avoidance responses in rat." <i>J Ethnopharmacol</i> , 5:205-214 (1982).	
	SINGH HK, RASTOGI RP, SRIMAL RC, DHAWAN BN. "Effect of bacosides A and B on avoidance responses in rats." <i>Phytother Res</i> , 2:70-75 (1988).	
	BHATTACHARYA SK, GHOSAL S. "Anxiolytic activity of a standardized extract of <i>Bacopa monniera</i> : An experimental study." <i>Phytomed</i> , 5:77-82 (1998).	

Examiner	Date	
Signature	Considered	

Form PT0	Q/SB/08A			Complete if Known	
				Application Number	10/519,515
		DISCLO		Filing Date	December 7, 2004
STATE	STATEMENT BY APPLICANT			First Named Inventor	Kyl L. Smith
///	(use as many sheets as necessary) Sheet 12 of 29			Group Art Unit	1654
(use a				Examiner Name	Not Yet Assigned
Sheet				Attorney Docket Number	681132-2US

U.S. PATENT DOCUMENTS							
Exr Initials	U.S. Patent Document		Name of First Inventor of Cited Document	Date of Publication of			
	Number	Kind Code (if known)		Cited Document MM-YYYY			

			FOREIGN PATE	NT DOCUMENTS		
Exr Initials	Country Code	Foreign Patent Docume Number	Kind Code (if known)	Name of Applicant of Cited Document	Date of Publication of Cited Document MM-YYYY	T₁

	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Exr Initials	Include Name of first Author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), volume-issue number(s), page(s), date (in parentheses). If a book, also include publisher and city and/or county where published.	T ₁
	DAR A, CHANNA S. "Calcium antagonistic activity of Bacopa monniera on vascular and	
	intestinal smooth muscles of rabbit and guinea-pig." J Ethnopharmacol, 66:167-174 (1999).	ļ
	SINGH RH, LALLAN S. "Studies on the anti-anxiety effect of the Medhya Rasayana drug,	
	Brahmi {Bacopa monniera Wettst.) - Part 1." J Res Ayurveda Siddha, 1133-148 (1980).	
	GHOSH S, KAR SK. "Clinical trial on Brahmi - Part II. Psychological investigation with	
	normals." <i>J Exptl Med Sci</i> , 10:12-13 (1996).	<u> </u>
	SHARMA R, CHATURVEDI C, TEWARI PV. "Efficacy of Bacopa monnieri in revitalizing	
	intellectual functions in children." J Res Indian Med, 3:1-17 (1987).	
	SHARMA, R., C. CHATURVEDIE AND P.V. TEWARI. "Management of Tropical	
	Pulmonary Eosinophilia in Children with Ayurvedic Drugs," J Res Indian Med 1987;	}
	3:1 -2.	
	ABHANG R. "Study to evaluate the effect of a micro (Suksma) medicine derived from Brahmi	1
	(Herpestris monierrd) on students of average intelligence." J Res Ayurvedia Siddha, 14:10-24	
,	(1993).	
	MARTIS G, RAO A, KARANTH KS. "Neuropharmacological activity of Herpestis monniera."	
	Fitoterapia, 63:3 99-404 (1992).	1
	SARA SJ, DEVAUGES V. "Priming stimulation of locus coeruleus facilitates memory retrieval in the rat." <i>Brain Res</i> , 438:299-303 (1988).	
	DENOBLEVJ. "Vinpocetine enhances retrieval of a step-through passive avoidance response in rats." <i>Pharmacol Biochem Behavior</i> , 26:183-186 (1987).	
	GROO D, PALOSI E, SZPORNY L. "Comparison of the effects of vinpocetine, vincamine, and	
	nicergoline on the normal and hypoxia-damaged learning process in spontaneously hypertensive	
	rats." Drug Develop Res, 15:75-85 (1988).	
	BENCSATH P, DEBRECZENI L, TAKACS L. "Effect of ethyl apovincaminate on cerebral	
	circulation of dogs under normal conditions and in arterial hypoxia." Arzneim-Forsch (Drug	
	Res), 26:1920-1923 (1976).	<u> Т </u>

Examiner	Date
Signature	Considered

Form PT	O/SB/08A			Complete if Known		
				Application Number	10/519,515	
	MATION			Filing Date	December 7, 2004	
STATE	MENT B	Y APPL	LICANT	First Named Inventor	Kyl L. Smith	
				Group Art Unit	1654	
(use as many sheets as necessary)			ecessary)	Examiner Name	Not Yet Assigned	
Sheet	Sheet 13 of 29		Attorney Docket Number	681132-2US		

	U.S. PATENT DOCUMENTS							
Exr Initials	U.S. Patent Document		Name of First Inventor of Cited Document	Date of Publication of				
	Number	Kind Code (if		Cited Document				
	1	known)		MM-YYYY				
			-					

	FOREIGN PATENT DOCUMENTS							
Exr Initials	Country Code	Foreign Patent Docum Number	Nent Kind Code (if known)	Name of Applicant of Cited Document	Date of Publication of Cited Document MM-YYYY	T ₁		

	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Exr Initials	Include Name of first Author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), volume-issue number(s), page(s), date (in parentheses). If a book, also include publisher and city and/or county where published.	T ₁
	RISCHKE R, KRIEGLSTEIN J. "Protective effect of vinpocetine against brain damage caused by	
	ischemia." <i>Japn J Pharmacol</i> , 56:349-356 (1991).	
ĺ	SAUER D, RISCHKE R, BECK T, ROBBERG C, MENNEL H-D, BIELENBERG GW,	
	KRIEGLSTEIN J. "Vinpocetine prevents ischemic cell damage in rat hippocampus." Life	
	Sci,43:1733-1739 (1988).	
	LAKICS V, SEBESTYEN MG, ERDO SL. "Vinpocetine is a highly potent neuroprotectant	
	against vertridine-induced cell death in primary cultures of rat cerebral cortex." NeurosciLett,	
	185:127-130 (1995).	
	NICHOLSON CD. "Pharmacology of nootropics and metabolically active compounds in relation	
	to their use in dementia." Psychopharmacol, 101:147-159 (1990).	
	TRETTER L, ADAM-VIZI V. "The neuroprotective drug vinpocetine prevents veratridine-	
	induced [Na J\ and [Ca], rise in synaptosomes." NeuroReport, 9:1849-1853 (1998).	
	ERDO SL, CAI N-S, WOLFF JR., KISS B. "Vinpocetine protects against excitotoxic cell death	•
	in primary cultures of rat cerebral cortex." Eur J Pharmacol, 187:551-553 (1990).	
	MIYAMOTO M, MURPHY TH, SCHNAAR RL, COYLE JT. "Antioxidants protect against	
	glutamate-induced cytotoxicity in a neuronal cell line." J Pharmacol Exptl Ther, 250:1132-1140	
Ĺ	(1989).	
	ISHIHARA K, KATSUKI H, SUGIMURA M, SATOH M. "Idebenone and vinpocetine augment	
	long-term potentiation in hippocampal slices in the guinea pig." Neuropharmacol, 28:569-573	
	(1989).	
	COLESTON DM, HINDMARCH I. "Possible memory-enhancing properties of vinpocetine."	
	Drug Develop Res, 14:191-193 (1988).	
	PAULO T, TOTH PT, NGUYEN TT, FORGACS L, TOROK TL, MAGYAR K.	
:	"HJNoradrenaline-releasing action of vinpocetine in the isolated main pulmonary artery of the	
	rabbit." J Pharm Pharmacol, 38:668-673 (1986).	

Examiner	Date
Signature	Considered

Form PT0	O/SB/08A	•		Filing Date December 7, 2004 First Named Inventor Kyl L. Smith Group Art Unit 1654		
<u>`</u>				Application Number	10/519,515	
li .		DISCL		Filing Date	December 7, 2004	
STATEMENT BY APPLICANT			LICANT	First Named Inventor	Kyl L. Smith	
(,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		note ee n		Group Art Unit	1654	
(use a	(use as many sheets as necessary)		ecessary)	Examiner Name	Not Yet Assigned	
Sheet	14	of	29	Attorney Docket Number	681132-2US	

	U.S. PATENT DOCUMENTS							
Exr Initials	U.S. Patent Document		Name of First Inventor of Cited Document	Date of Publication of				
	Number	Kind Code (if known)		Cited Document MM-YYYY				

	FOREIGN PATENT DOCUMENTS							
Exr Initials	Country Code	Foreign Patent Document Number	Kind Code (if known)	Name of Applicant of Cited Document	Date of Publication of Cited Document MM-YYYY	T ₁		

	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Exr Initials	Include Name of first Author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), volume-issue number(s), page(s), date (in parentheses). If a book, also include publisher and city and/or county where published.	T ₁
	KARPATI E, SZPORNY L. "General and cerebral haemodynamic activity of ethyl	
	apovincaminate." Arzneim-Forsch (Drug Res), 26:108-1912 (1976).	
	IMAMOTO T, TANABE M, SHIMAMOTO N, KAWAZOE K, HIRATA M. "Cerebral	
	circulatory and cardiac effects of vinpocetine and its metabolite, apovincaminic acid, in	
	anesthetized dogs." Arzneim-Forsch (Drug Res), 34:161-169 (1984).	
	HAGIWARA M, ENDO T, HIDAKA H. "Effects of vinpocetine on cyclic nucleotide	
	metabolism in vascular smooth muscle." Biochem Pharmacol, 33:453-457(1984).	
	HADJIEV D, YANCHEVA S. "Rheoencephalographic and psychological studies with ethyl	
	apovincaminate in cerebral vascular insufficiency." Arzneim-Forsch (Drug Res), 26:1947-1950	
	(1976).	
	SHIBOTA M, KAKIHANA M, NAGAOKA A. "The effect of vinpocetine on the brain glucose	
	uptake in mice." Folia Pharmacol Japon, 80:221-224 (1982).	
	ROSDY B, BALAZS M, SZPORNY L. "Biochemical effect of ethyl apovincaminate." Arzneim-	
	Forsch (Drug Res), 26:1923-1926 (1976).	
	PANTANO P, BARON J-C, LEBRUN-GRANDIE P, DUQUESNOY N, BOUSSER M-G,	
	COMAR D. "Regional cerebral blood flow and oxygen consumption in human aging." Stroke	
	15:635-641 (1984).	
	MIYAZAKI M. "The effect of a cerebral vasodilator, vinpocetine, on cerebral vascular resistance	1
	evaluated by the Doppler ultrasonic technique in patients with cerebrovascular diseases."	
	Angiology, 46:53-58 (1995).	
	OTOMO E, ATARASHI J, ARAKI G, ITO E, OMAE T, KUZUYA F, NUKADA T, EBI O.	
	"Comparison of vinpocetine with ifenprodil tartrate and dihydroergotoxine mesylate treatment	
	and results of long-term treatment with vinpocetine." Curr Ther Res 19%5,37:%1 1-821.	<u></u>
	MANCONI E, BINAGHI F, PITZUS F. "A double-blind clinical trial of vinpocetine in the	
	treatment of cerebral insufficiency of vascular and degenerative origin." Curr Ther Res, 40:702-	
	709 (1986).	

Examiner	Date
Signature	Considered

Form PTC	Ç/SB/08A				Complete if Known
	NFORMATION DISCLOSURE			Application Number	10/519,515
				Filing Date	December 7, 2004
SIAIL	STATEMENT BY APPLICANT			First Named Inventor	Kyl L. Smith
/1150.2	e many che	ate se nace	accan/)	Group Art Unit	1654
(use a	(use as many sheets as necessary)		Examiner Name	Not Yet Assigned	
Sheet	Sheet 15 of 29			Attorney Docket Number	681132-2US

_	U.S. PATENT DOCUMENTS							
Exr Initials	U.S. Patent Document		Name of First Inventor of Cited Document	Date of Publication of				
	Number	Kind Code (if		Cited Document				
		known)		MM-YYYY				

	FOREIGN PATENT DOCUMENTS							
Exr Initials	Country Code	Foreign Patent Document Number	Kind Code (if known)	Name of Applicant of Cited Document	Date of Publication of Cited Document MM-YYYY	T₁		

	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Exr Initials	Include Name of first Author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), volume-issue number(s), page(s), date (in parentheses). If a book, also include publisher and city and/or county where published.	Т1
	BALESTRERI R, FONTANA L, ASTENGO F. "A double-blind placebo controlled evaluation of	
	the safety and efficacy of vinpocetine in the treatment of patients with chronic vascular senile cerebral dysfunction." J Am Geriatr Soc, 35:425-430 (1987).	
	HINDMARCH I, FUCHS H-H, ERZIGKEIT H. "Efficacy and tolerance of vinpocetine in	
	ambulant patients suffering from mild to moderate organic psychosyndromes." <i>Internal Clin Psychopharmacol</i> , 6:31-43 (1991).	
	SUBHAN Z, HINDMARCH I. "Psychopharmacological effects of vinpocetine in normal healthy volunteers." Eur J Clin Pharmacol, 28:567-571 (1985).	
	RICE-EVANS CA, MILLER NJ, PAGANGA G. "Structure-antioxidant activity relationships of flavonoids and phenolic acids." <i>Free Red Biol Med</i> , 20:933-956 (1996).	
	RIGO A, VIANELLO F, CLEMENTI G. "Contribution of proanthocyanidins to the peroxy radical scavenging capacity of some Italian red wines." <i>JAgric Food Chem</i> , 48:1996-2002 (2000).	
	BAGCHI D, GARG A, KROHN RL, BAGCHI DJ, BALMOORI J, STOHS SJ. "Protective effects of grape seed proanthocyanidins and selected antioxidants against TPA- induced hepatic and brain lipid peroxidation and DNA fragmentation, and peritoneal macrophage activation in mice." Gen Pharmacol, 30:771-776 (1998).	
	FREI B, KIM MC, AMES BN. "Ubiquinol-10 is an effective lipid-soluble antioxidant at physiological concentrations." <i>Proc NatlAcad Sci</i> , 87:4879-4883 (1990).	
	FACINO RM, CARINI M, ALDINI G, BOMBARDELLI E, MORAZZONI P, MORELLI R. "Free radicals scavenging action and anti-enzyme activities of procyanidines from <i>Vitis vinifera</i> ." <i>Arzneim-Forsch (Drug Res)</i> , 44:592-601 (1994).	
	BAGCHI B, GARG A, KROHN RL, BAGCHI M, TRAN MX, STOHS SJ. "Oxygen free radical scavenging abilities of vitamins C and E, and a grape seed proanthocyanidin extract in vitro." Res Commun Molecular Pathol Pharmacol, 95:179-189 (1997).	

Examiner	Date
Signature	Considered

Form PTC	O/SB/08A			Complete if Known			
				Application Number	10/519,515		
E .	INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Filing Date	December 7, 2004		
STATE				First Named Inventor	Kyl L. Smith		
(,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,				Group Art Unit	1654		
(use a	(use as many sheets as necessary)			Examiner Name	Not Yet Assigned		
Sheet	16	of	29	Attorney Docket Number	681132-2US		

	U.S. PATENT DOCUMENTS							
Exr Initials	U.S. Patent Document Number	Kind Code (if known)	Name of First Inventor of Cited Document	Date of Publication of Cited Document MM-YYYY				

			FOREIGN PATE	NT DOCUMENTS		
Exr Initials	Country Code	Foreign Patent Docume Number	ent Kind Code (if known)	Name of Applicant of Cited Document	Date of Publication of Cited Document MM-YYYY	T ₁

f	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Exr Initials	Include Name of first Author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), volume-issue number(s), page(s), date (in parentheses). If a book, also include publisher and city and/or county where published.	T ₁
	PACKER L, RIMBACH G, VIRGILI F. "Antioxidant activity and biologic properties of a	
	procyanidin-rich extract from pine (<i>Pinus maritimd</i>) bark, pycnogenol." <i>Free Rad Biol Med</i> , 27:704-724 (1999).	
	LIU FJ, ZHANG YX, LAU BHS. "Pycnogenol enhances immune and haemopoietic functions in	
	senescence-accelerated mice." Cell Mol Life Sci, 54:1168-1172 (1998).	
	SALAH N, MILLER NJ, PAGANGA G, TIJBURG L, BOLWELL GP, RICE-EVANS C.	
	"Polyphenolic flavonoids as scavengers of aqueous phase radicals and as chain- breaking	
	antioxidants." Arch Biochem Biophys, 322:339-346 (1995).	
	COSSINS E, LEE R, PACKER L. "ESR studies of vitamin C regeneration, order of reactivity of	
	natural source phytochemical preparations," Biochem Mol Biol Intern, 45:583-597 (1998).	
	SAIJA A, SCALESE M, LANZA M, MARZULLO D, BONINA F, CASTELLI F. "Flavonoids	
	as antioxidant agents: Importance of their interaction with biomembranes". <i>Free Rad Biol Med</i> , 19:481-486 (1995).	
	RONG Y, LI L, SHAH V, LAU BHS. "Pycnogenol protects vascular endothelial cells from r-butyl hydroperoxide induced oxidant injury." <i>Biotechnol Ther</i> , 5:117-126 (1994-1995).	
	WEI ZH, PENG QL, LAU BHS. "Pycnogenol enhances endothelial cell antioxidant defenses." <i>Redox Report</i> , 3:219-224 (1997).	
	KIM J, CHEHADE J, PINNAS JL, MOORADIAN AD. "Effect of select antioxidants on	
	malondialdehyde modification of proteins." Nutrition, 16:1079-1081 (2000).	
	UEDA T, UEDA T, ARMSTRONG D. "Preventive effect of natural and synthetic antioxidants	
	on lipid peroxidation in the mammalian eye." Ophthalmic Res, 28:184-192 (1996).	
	KOBAYASHI MS, HAN D, PACKER L. "Antioxidants and herbal extracts protect HT-4	
	neuronal cells against glutamate-induced cytotoxicity." Free Rad Res, 32:115-124 (2000).	
	COYLE JT, PUTTFARCKEN P. "Oxidative stress, glutamate, and neurodegenerative	
	disorders." Science, 262:689-695 (1993).	

Examiner	Date
Signature	Considered

Form PTC	D/SB/08A		•	Complete if Known			
1				Application Number	10/519,515		
1	INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Filing Date	December 7, 2004		
STATE				First Named Inventor	Kyl L. Smith		
(1100.0	(use as many sheets as necessary)			Group Art Unit	1654		
(use a				Examiner Name	Not Yet Assigned		
Sheet	17	of	29	Attorney Docket Number	681132-2US		

U.S. PATENT DOCUMENTS							
Exr Initials	U.S. Patent Document		Name of First Inventor of Cited Document	Date of Publication of			
	Number	Kind Code (if known)		Cited Document MM-YYYY			

	FOREIGN PATENT DOCUMENTS						
Exr Initials	Country Code	Foreign Patent Docum Number	Kind Code (if known)	Name of Applicant of Cited Document	Date of Publication of Cited Document MM-YYYY	T ₁	

	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Exr Initials	Include Name of first Author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), volume-issue number(s), page(s), date (in parentheses). If a book, also include publisher and city and/or county where published.	T ₁
	OLNEY JW. "Brain lesions, obesity, and other disturbances in mice treated with monosodium	
	glutmate." Science, 164:719-721 (1969).	
	PEREIRA CMF, OLIVEIRA CR. "Glutamate toxicity ona PC 12 cell line involves glutathione	
	(GSH) depletion and oxidative stress." Free Rad Biol Med, 23:637-647 (1997).	
	FITZPATRICK DF, BING B, ROHDEWALD P. "Endothelium-dependent vascular effects of	
	pycnogenol." J Cardiovasc Pharmacol, 32:509-515 (1998).	
	SCHMIDT HHHW, WALTER U. "No at work" Cell, 78:919-925 (1994).	
	FREMONT L, BELGUENDOUZ L, DELPAL S. "Antioxidant activity of resveratrol and	
	alcohol-free wine polyphenols related to LDL oxidation and polyunsaturated fatty acids." Life Sci,	
	64:2511 -2521 (1999).	<u></u>
	CHEN CK, PACE-ASCIAK CR. "Vasorelaxing activity of resveratrol and quercetin in isolated	
	rat aorta." Gen Pharmacol, 27:363-366 (1996).	
	ABALAN F. "Primer in folic acid: Folates and neuropsychiatry." Nutrition, 15:595-598 (1999).	
	ALPERT JE, FAVA M. "Nutrition and depression: The role of folate." <i>NutrRev</i> , 55:145-149	
	(1997).	
	ABOU-SALEH MT, COPPEN A. "The biology of folate in depression: Implications for	
	nutritional hypotheses of the psychoses." J Psychiat Res, 20:91-101 (1986).	ļ
	BOTTIGLIERI T, LAUNDY M, CRELLIN R, TOONE BK, CARNEY MWP, REYNOLDS EH.	ļ
	"Homocysteine, folate, methylation, and monoamine metabolism in depression." J Neurol	
	Neurosurg Psychiatry, 69:228-232 (2000).	
	ENZI G. "Folate status and cognitive impairment." Aging Clin Exp Res, 6:69-72 (1994).	
	ORTEGA RM, MANAS LR, ANDRES P, GASPAR MJ, AGUDO FR, JIMENEZ A, PASCUAL	
	T. "Functional and psychic deterioration in elderly people may be aggravated by folate	
	deficiency." JNutr,126:1992-1999 (1996).	

Examiner	Date	
Signature	Considered	

Form PT	O/SB/08A				Complete if Known	
				Application Number	10/519,515	
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Filing Date	December 7, 2004	
STATE				First Named Inventor	Kyl L. Smith	
4				Group Art Unit	1654	
(use a	(use as many sheets as necessary)			Examiner Name	Not Yet Assigned	
Sheet	18	of	29	Attorney Docket Number	681132-2US	

U.S. PATENT DOCUMENTS							
Exr Initials	U.S. Patent Document		Name of First Inventor of Cited Document	Date of Publication of			
	Number	Kind Code (if known)		Cited Document MM-YYYY			

	FOREIGN PATENT DOCUMENTS								
Exr Initials	Country Code	Foreign Patent Docun Number	Kind Code (if known)	Name of Applicant of Cited Document	Date of Publication of Cited Document MM-YYYY	T ₁			

[OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Exr Initials	Include Name of first Author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), volume-issue number(s), page(s), date (in parentheses). If a book, also include publisher and city and/or county where published.	T ₁
	FAVA M, BORUS JS, ALPERT JE, NIERENBERG AA, ROSENBAUM JF, BOTTIGLIERI T.	
	"Folate, vitamin B12, and homocysteine in major depressive disorder." <i>Am J Psychiatry</i> , 154:426-428 (1997).	
	LEVITT AJ, JOFFE RT. "Folate, B12, and life course of depressive illness." <i>Biol Psychiatry</i> ,	
	25:867-872 (1989).	
	GHADIRIAN AM, ANANTH J, ENGELSMANN F. "Folic acid deficiency and depression." <i>Psychosomatics</i> , 21:926-929 (1980).	
	PRAKASH R, PETRIE WM. "Psychiatric changes associated with an excess of folic acid." Am J	
	Psychiatry, 139:1192-1193 (1982).	<u> </u>
	CLARKE R, SMITH AD, JOBST KA, REFSUM H, SUTTON L, UELAND PM. "Folate,	
	vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease." Arch	
	Neurol, 55:1449-1455 (1998).	<u> </u>
	RIGGS KM, SPIRO A, TUCKER K, RUSH D. "Relations of vitamin B-12, vitamin B-6, folate,	
	and homocysteine to cognitive performance on the Normative Aging Study." <i>Am J Clin Nutr</i> , 63:306-314 (1996).	
	SNOWDON DA, TULLY CL, SMITH CD, RILEY KP, MARKESBERY WR. "Serum folate	
	and the severity of atrophy of the neocortex in Alzheimer disease: Findings from the Nun study."	
	Am J Clin Nutr, 1:993-998 (2000).	
	CARNEY M, SHEFFIELD BF. "Associations of subnormal serum folate and vitamin B12 and	
	effects of replacement therapy." JNerv Merit Dis, 150:404-412 (1970).	
	LEVITT AJ, WESSON VA, JOFFE RT. "Impact of suppression of thyroxine on folate status	
	during acute antidepressant therapy." Psychiatry Res, 79:123-129 (1998).	
	CRAYHON R. "The clinical applications of folk acid." Jamer Neutraceutical Assoc, 4:21-26	
	(2001).	

Signature Considered	Examiner	Date	
	Signature	Considered	

Form PT0	D/SB/08A			Complete if Known		
				Application Number	10/519,515	
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Filing Date	December 7, 2004	
STATE				First Named Inventor	Kyl L. Smith	
(,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	(ver as many shoots as passage)			Group Art Unit	1654	
(use a	(use as many sheets as necessary)			Examiner Name	Not Yet Assigned	
Sheet	19	of	29	Attorney Docket Number	681132-2US	

U.S. PATENT DOCUMENTS							
Exr Initials	U.S. Patent Document		Name of First Inventor of Cited Document	Date of Publication of			
	Number	Kind Code (if known)		Cited Document MM-YYYY			

	FOREIGN PATENT DOCUMENTS							
Exr Initials	Country Code	Foreign Patent Docume Number	Kind Code (if known)	Name of Applicant of Cited Document	Date of Publication of Cited Document MM-YYYY	T ₁		

	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Exr Initials	Include Name of first Author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), volume-issue number(s), page(s), date (in parentheses). If a book, also include publisher and city and/or county where published.	T ₁
	UBBINK JB. "Should all elderly people receive folate supplements?" <i>Drugs Aging</i> , 13:415-420 (1998).	
	KAUWELL GP, LIPPERT BL, WILSKY CE, HERRLINGER-GARCIA K, HUTSON AD, THERIAQUE DW, RAMPERSAUD GC, CERDA JJ, BAILEY LB. "Folate status of elderly women following moderate folate depletion responds only to a higher folate intake." <i>JAfa/r</i> , 130:1584-1590 (2000).	
	LANDGREN F, ISRAELSSON B, LINDGREN A, HULTBERG B, ANDERSSON A, BRATTSTROM L. "Plasma homocysteine in acute myocardial infarction: Homocysteine-lowering effect of folic acid." <i>J Intern Med</i> , 237:381-388 (1995).	
	KELLY PJ, ROSAND J, PLOMARITOGLOU A, CHANG Y, KISTLER JP, FURIE KL. "Mild-to-moderate hyperhomocyst(e)inemia and risk of stroke. Result of a meta-analysis." <i>Stroke</i> , 32:366 (2000).	
	MALINOW MR, NIETO FJ, SZKLO M, CHAMBLESS LE, BOND G. "Carotid artery intinal-medial wall thickening and plasma homocyst(e) ine in asymptomatic adults." <i>The Atherosclerosis Risk in Communities Study</i> . Circulation, 87:1107-1113 (1993).	
	SELHUB J, JACQUES PJ, BOSTOM AG, D'AGOSTINO RB, Wilson PWF, Belanger AJ, O'Leary DH, Wolf PA, Rush D, Schaefer EJ, Rosenberg IH. "Relationship between plasma homocysteine, vitamin status and extracranial carotid artery stenosis in the Framingham study population." <i>JNutr</i> , 126:1258S-1265S (1996).	

Examiner	Date
Signature	Considered

Form PT0	D/SB/08A			Complete if Known		
				Application Number	10/519,515	
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Filing Date	December 7, 2004	
STATE	MENTB	APPLI	CANT	First Named Inventor	Kyl L. Smith	
(,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		-t	******	Group Art Unit	1654	
(use a	(use as many sheets as necessary)			Examiner Name	Not Yet Assigned	
Sheet	20	of	29	Attorney Docket Number	681132-2US	

U.S. PATENT DOCUMENTS							
Exr Initials	U.S. Patent Document		Name of First Inventor of Cited Document	Date of Publication of			
	Number	Kind Code (if known)		Cited Document MM-YYYY			

FOREIGN PATENT DOCUMENTS							
Exr Initials	Country Code	Foreign Patent Docum Number	Kind Code (if known)	Name of Applicant of Cited Document	Date of Publication of Cited Document MM-YYYY	T₁	

	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Exr Initials	Include Name of first Author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), volume-issue number(s), page(s), date (in parentheses). If a book, also include publisher and city and/or county where published.	T ₁
	PANCHARUNITI N, LEWIS CA, SAUBERLICH HE, PERKINS LL, GO RCP, ALVAREZ JO,	
	MACALUSO M, ACTON RT, COPELAND RB, COUSINS AL, GORE TB, CORNWELL PE,	
	ROSEMAN JM. "Plasma homocyst(e)ine, folate, and vitamin B-12 concentrations and risk for	
	early-onset coronary artery disease." Am J Clin Nutr, 59:940- 948 (1994).	
	STAMPFER MJ, MALINOW R, WILLETT WC, NEWCOMER LM, UPSON B, ULLMANN D,	
	TISHLER PV, HENNEKENS CH. "A prospective study of plasma homocyst(e) ine and risk of myocardial infarction in US physicians." <i>JAMA</i> , 268:877-881 (1992).	
	SELHUB J, JACQUES PF, BOSTOM AG, D'AGOSTINO RB, WILSON PWF, BELANGER	
	AJ, O'LEARY DH, WOLF PA, SCHAEFER EJ, ROSENBERG IH. "Association between	
	plasma homocysteine concentrations and extracranial carotid-artery stenosis." <i>New Engl J Med</i> , 332:286-291 (1995).	
-	CLARKE R, DALY L, ROBINSON K, NAUGHTEN E, CAHALANE S, FOWLER B,	
	GRAHAM I. "Hyperhomocysteinernia: An independent risk factor for vascular disease." New EnglJMed \9932A:\U9-U55.	
	BOUSHEY CJ, BERESFORD SAA, OMENN GS, MOTULSKY AG. "A quantitative	
	assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of	
	increasing folic acid intakes." JAMA, 274:1049-1057 (1995).	
	KANG S-S, WONG PWK, MALINOW MR. "Hyperhomocyst(e)mia as a risk factor for	
<u> </u>	occlusive vascular disease." Annu Rev Nutr, 12:279-298 (1992).	
	EVERS S, KOS HG, GROTENMEYER KH, et al. "Features, symptoms, and	
	neurophysiological findings in stroke associate with hyperhomocysteinemia." ArchNeurol,	
<u> </u>	54:1276 (1997).	
	PERNA AF, DE SANTO NG, INGROSSO D. "Adverse effects of hyperhomocysteinemia and	
<u></u>	their management by folic acid. "Miner Electrolyte Metab, 23:174-178 (1997).	

Examiner	Date	
Signature	Considered	

Form PTO/SB/08A					Complete if Known	
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Application Number	10/519,515	•
				Filing Date	December 7, 2004	
STATE				First Named Inventor	Kyl L. Smith	
(,,,,,	(use as many sheets as necessary)			Group Art Unit	1654	
(use a				Examiner Name	Not Yet Assigned	
Sheet	21	of	29	Attorney Docket Number	681132-2US	

U.S. PATENT DOCUMENTS						
Exr Initials	U.S. Patent Document		Name of First Inventor of Cited Document	Date of Publication of		
	Number	Kind Code (if known)		Cited Document MM-YYYY		

Date of
nt of Cited Document Publication of Cited Document MM-YYYY
-

	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Exr Initials	Include Name of first Author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), volume-issue number(s), page(s), date (in parentheses). If a book, also include publisher and city and/or county where published.	T ₁
	HARKER LA, ROSS R, SLICHTER SJ, SCOTT CR. "Homocysteine-induced arteriosclerosis.	
	The role of endothelial cell injury and platelet response in its genesis." <i>JClin Invest</i> , 58:731-741 (1976).	
	BLANN AD. "Endothelial cell damage and homocysteine." Atherosclerosis, 94:89-91 (1994).	
	LA RUE A, KOEHLER KM, WAYNE SJ, CHIULLI SJ, HAALAND KY, GARRY PJ.	
	"Nutritional status and cognitive functioning in a normally aging sample: A 6-yr reassessment." Am JClin Nutr, 65:20-29 (1997).	
	LIPTON SA, KIM WK, CHOI YB, KUMAR S, D'EMILIA DM, RAYUDU PV, ARNELLE	
	DR, STAMLER JS. "Neurotoxicity associated with dual actions of homocysteine at the N-	
	methyl-D-aspartate receptor." Proc Natl Acad Sci, 94:5923-5928 (1997).	l
	BEAL MF, SWARTZ KJ, FINN SF, MAZUREK MF, KOWALL NW. "Neurochemical	
	characterization of excitotoxin lesions in the cerebral cortex." JNeurosci, 11:147-158 (1991).	
	UBBINK JB, VAN DER MERWE A, VERMAAK WJH, DELPORT R.	
	"Hyperhomocysteinemia and the response to vitamin supplementation." <i>Clin Invest</i> , 71:993-998 (1993).	
	BROUWER I A, VAN DUSSELDORP M, THOMAS CMG, DURAN M, HAUTVAST JGAJ,	
	ESKES TKAB, STEEGERS-THEUNISSEN RPM. "Low-dose folic acid supplementation	
	decreases plasma homocysteine concentrations: A randomized trial". Am J Clin Nutr, 69:99-104	
	(1999).	
	BUNOUT D, GARRIDO A, SUAZO M, KAUFFINN R, VENEGAS P, DE LA MAZA P,	
	PETERMANN M, HIRSCH S. "Effects of supplementation with folic acid and antioxidant	
	vitamins on homocysteine levels and LDL oxidation in coronary patients." Nutrition, 16:107-110	
	(2000).	

Examiner	Date	
Signature	Considered	

Form PT0	O/SB/08A					
INFORMATION DISCLOSURE				Application Number	10/519,515	
				Filing Date	December 7, 2004	
STATE	STATEMENT BY APPLICANT			First Named Inventor	Kyl L. Smith	
				Group Art Unit	1654	
(use a	is many si	heets as ne	ecessary)	Examiner Name	Not Yet Assigned	
Sheet	22	of	29	Attorney Docket Number	681132-2US	

U.S. PATENT DOCUMENTS						
Exr Initials	U.S. Patent Document Number	Kind Code (if	Name of First Inventor of Cited Document	Date of Publication of Cited Document MM-YYYY		
		known)		141141		

		FC	DREIGN PATE	NT DOCUMENTS		
Exr Initials	Country Code	Foreign Patent Document Number	Kind Code (if known)	Name of Applicant of Cited Document	Date of Publication of Cited Document MM-YYYY	T ₁
			-			

	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Exr Initials	Include Name of first Author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), volume-issue number(s), page(s), date (in parentheses). If a book, also include publisher and city and/or county where published.	T₁
	CLARKE R, ARMITAGE J. "Vitamin supplements and cardiovascular risk: Review of the	
	randomized trials of homocysteine-lowering vitamin supplements." Sem Thromb Hemostas 2000, 26:341-348.	
	"Homocysteine Lowering Trialsists' Collaboration. Lowering blood homocysteine with folic acid	
	based supplements: Meta-analysis of randomized trials." <i>Br MedJ</i> , 316:894-898 (1998).	
	WOO KS, CHOOK P, LOLIN YI, SANDERSON JE, METREWELI C, CELERMAJER DS.	
	"Folic acid improves arterial endothelial function in adults with hyperhomocysteinemia." JAm Coll	
	Cardiol, 34:2002-2006 (1999).	<u> </u>
	CARNEY MWP, TOONE BK, REYNOLDS EH. "S-Adenosylmethionine and affective	
	disorder." Am J Med, 83(suppl 5A): 104-106 (1987).	
	SHANE B. "Vitamin B12-Folate interrelationships." Annu Rev Nutr, 5:115-141 (1985).	
	SHEVELL MI, ROSENBLATT DS. "The neurology of cobalamin." Can JNeurol Sci, 19:472-486 (1992).	
	HECTOR M, BURTON JR. "What are the psychiatric manifestations of vitamin B12 deficiency?" <i>JAm Geriatr Soc</i> , 36:1105-1112 (1987).	
	MITSUYAMA Y, KOGOH H. "Serum and cerebrospinal fluid vitamin Bl2 levels in demented patients with CH3-B12 treatment - preliminary study." <i>Jpn JPsychiatr Neurol</i> , 42:65-71 (1988).	
	LINDENBAUM J, HEALTON EB, SAVAGE DG, BRUST JCM, GARRETT TJ, PODELL ER,	
	MARCELL PD, STABLER SP, ALLEN RH. "Neuropsychiatric disorders caused by cobalamin	
<u> </u>	deficiency in the absence of anemia or macrocytosis." New Engl.J Med, 318:1720-1728 (1988).	
	BOHNEN N, JOLLES J, DEGENAAR CP. "Lower blood levels of vitamin B12 are related to	
	decreased performance of healthy subjects in the Stroop color-word test." Neurosci Res	
	Commun, 11:53-56 (1992).	

Examiner	Date	
Signature	Considered	

Form PT	O/SB/08A				Complete if Known	
				Application Number	10/519,515	
INFORMATION DISCLOSURE				Filing Date	December 7, 2004	
STATE	STATEMENT BY APPLICANT			First Named Inventor	Kyl L. Smith	-
((use as many sheets as necessary)			Group Art Unit	1654	
(use a				Examiner Name	Not Yet Assigned	
Sheet	23	of	29	Attorney Docket Number	681132-2US	

U.S. PATENT DOCUMENTS							
Exr Initials	U.S. Patent Document Number	Kind Code (if known)	Name of First Inventor of Cited Document	Date of Publication of Cited Document MM-YYYY			

	FOREIGN PATENT DOCUMENTS									
Exr Initials	Country Code	Foreign Patent Documen Number	Kind Code (if known)	Name of Applicant of Cited Document	Date of Publication of Cited Document MM-YYYY	T₁				

	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Exr Initials	Include Name of first Author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), volume-issue number(s), page(s), date (in parentheses). If a book, also include publisher and city and/or county where published.	T ₁
	GOODWIN JS, GOODWIN JM, GARRY PJ. "Association between nutritional status and	
	cognitive functioning in a healthy elderly population." <i>JAMA</i> , 249:2917-2921 (1983).	
	HEALTON EB, SAVAGE DG, BRUST JCM, GARRETT TJ, LINDENBAUM J. "Neurologic	
	aspects of cobalamin deficiency." Medicine, 70:229-245 (1991).	
	CARMEL R. "Subtle and atypical cobalamin deficiency states." AmJHematol, 34:108-114	
	(1990).	
	MITTENBERG W, SEIDENBERG M, O'LEARY DS, DIGIULIO DV. "Changes in cerebral	
	functioning associated with normal aging." J Clin Exptl Neuropsychol, 11:918-932 (1989).	
	TETRUD JW, LANGSTON JW. "The effect of deprenyl (selegiline) on the natural history of	
	Parkinson's disease." Science, 245:519-522 (1989).	
	AMERICAN MEDICAL ASSOCIATION. "Thiamin addition to alcohol." Proceedings, 5(f*	
	Interim Meeting, American Medical Association.	
	TUCKER DM, PENLAND JG, SANDSTEAD HH, MILNE DB, HECK DG, KLEVAY LM.	
	"Nutrition status and brain function in aging." Am J Clin Nutr, 52:93-102 (1990).	
	KLIMESCH W, SCHIMKE H, LADURNER G, PFURTSCHELLER G. "Alpha frequency and	
	memory performance." JPsychophysiol, 4:381-390 (1990).	ļ
	LONSDALE D, SHAMBERGER RJ. "Red cell transketolase as an indicator of nutritional	
	deficiency." Am J Clin Nutr, 33:205-211 (1980).	
	BENTON D, FORDY J, HALLER J. "The impact of long-term vitamin supplementation on	
	cognitive functioning." Psychopharmacol, 117:298-305 (1995).	
	BENTON D, GRIFFITHS R, HALLER J. "Thiamine supplementation mood and cognitive	
	functioning." Psychopharmacol, 129:66-71 (1997).	
	ROOT EJ, LONGNECKER JB. "Brain cell alterations suggesting premature aging induced by	
	dietary deficiency of vitamin B6 and/or copper." Am J Clin Nutr, 37:540-552 (1983).	

Examiner	Date	
Signature	Considered	

Form PT	O/SB/08A			Complete if Known		
				Application Number	10/519,515	
	MATION			Filing Date	December 7, 2004	
STATE	MENT B	Y APPL	ICANT.	First Named Inventor	Kyl L. Smith	
(,,,,,				Group Art Unit	1654	
(use a	(use as many sheets as necessary)			Examiner Name	Not Yet Assigned	
Sheet	24	of	29	Attorney Docket Number	681132-2US	

U.S. PATENT DOCUMENTS							
Exr Initials	U.S. Patent Document		Name of First Inventor of Cited Document	Date of Publication of			
	Number	Kind Code (if known)		Cited Document MM-YYYY			

	FOREIGN PATENT DOCUMENTS									
Exr Initials	Country Code	Foreign Patent Docum Number	ent Kind Code (if known)	Name of Applicant of Cited Document	Date of Publication of Cited Document MM-YYYY	T ₁				
		•••								

	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Exr Initials	Include Name of first Author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), volume-issue number(s), page(s), date (in parentheses). If a book, also include publisher and city and/or county where published.	T ₁				
	MERRILL AH, JR, HENDERSON JM. "Diseases associated with defects in vitamin B6					
	metabolism or utilization." Annu Rev Nutr, 7:137-156 (1987).					
	DAKSHINAMURTI K, LEBLANCQ WD, HERCHL R, HAVLICEK V. "Nonparallel changes in					
	brain monoamines of pyroxidine-deficient growing rats." Exp Brain Res, 26:355-366 (1976).					
	SIOW YL, DAKSHINAMURTI K. Effect of pyridoxine deficiency on aromatic L- amino acid					
	decarboxylase in adult rat brain. Exp Brain Res, 59:575-581 (1985).					
	STEWART JW, HARRISON W, QUITKIN F, BAKER H. "Low B6 levels in depressed					
	outpatients." Biol Psychiatry, 19:613-616 (1984).					
	CARNEY MWP. "Vitamin deficiency and mental symptoms." BrJPsychiat, 156:878-882					
	(1990).					
	KRETSCH MJ, SAUBERLICH HE, NEWBRUN E. "Electroencephalographic changes and					
	periodontal status during short-term vitamin B-6 depletion of young, nonpregnant women." Am J					
	Clin Nutr, 53:1266-1274 (1991).					
	ADAMS PW, WYNN V, ROSE DP, SEED M, FOLKARD J, STRONG R. "Effect of					
	pyridoxine hydrochloride (vitamin B6) upon depression associated with oral contraception."					
	Lancet, 1:897-904 (1973).	<u> </u>				
	HALLERT C, ASTROM J, WALAN A. "Reversal of psychopathology in adult celiac disease					
	with the aid of pyridoxine (vitamin B6)." Scand J Gastroenterol, 18:299-304 (1983).					
	DEIJEN JB, VAN DER BEEK EJ, ORLEBEKE JF, VAN DEN BERG H. "Vitamin B-6					
	supplementation in elderly men: Effects on mood, memory, performance and mental					
	effort." Psychopharmacoll992,109AS9-496.					
	BUETTNERGR. "The pecking order of free radicals and antioxidants: Lipid					
	peroxidation, -tocopherol and ascorbate." Arch Biochem Biophys, 300:535-543 (1993).					
	SCHMIDT R, HAYN M, REINHART B, ROOB G, SCHMIDT H, SCHUMACHER M,					
	WATZINGER N, LAUNER LJ. "Plasma antioxidants and cognitive performance in					
	middle-aged and older adults: Results of the Austrian Stroke Prevention Study." J Am					
	Geriatr Soc, 46:1407-1410 (1998).					
Exami						
Signat	ure Considered	_				

Form PTC)/SB/08A			Complete if Known		
				Application Number	10/519,515	
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Filing Date	December 7, 2004	
SIAIE	MENIR	r APPL	ICANI	First Named Inventor	Kyl L. Smith	
/uso o	(Group Art Unit	1654	
(use as many sheets as necessary)			cessary)	Examiner Name	Not Yet Assigned	
Sheet	25	of	29	Attorney Docket Number	681132-2US	

	U.S. PATENT DOCUMENTS							
Exr Initials U.S. Patent Document Name of First Inventor of Cited Document Date of Publication of								
	Number	Kind Code (if known)		Cited Document MM-YYYY				

	FOREIGN PATENT DOCUMENTS								
		Foreign Patent Documer	nt		Date of	T ₁			
Exr Initials	Country Code	Number	Kind Code (if known)	Name of Applicant of Cited Document	Publication of Cited Document MM-YYYY				
	(

	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	т =			
Exr Initials	Include Name of first Author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), volume-issue number(s), page(s), date (in parentheses). If a book, also include publisher and city and/or county where published.	T ₁			
	BEARD JL, CONNOR JD, JONES BC. "Brain iron: Location and function." Prog Food				
	SciNutrSci\993,17:m-22\.				
	Kretsch MJ, Fong AKH, Green MW, Johnson HL. Cognitive function, iron status, and				
	hemoglobin concentration in obese dieting women. Eur J Clin Nutr 1998,52:512-518.				
	DALLMAN PR. "Biochemical basis for the manifestations of iron deficiency." Annu Rev Nutr,				
	6:13-40 (1986).	-			
	POLLITT E. "Iron deficiency and cognitive function," <i>Annu Rev Nutr</i> , 13:521-537 (1993).	<u> </u>			
	DALLMAN PR, SIIMES MA, STEKEL A. "Iron deficiency in infancy and childhood."	1			
	AmJClinNutr, 33:86-118 (1980).				
	POLLITT E, LEIBEL RL. "Iron deficiency and behavior." <i>JPediatr</i> , 88:372-381 (1976).				
	BRUNER AB, JOFIFE A, DUGGAN AK, CASELLA JF, BRANDT J. "Randomized study of	1			
	cognitive effects of iron supplementation in non-anemia iron-deficient adolescent girls." Lancet,				
<u> </u>	348:992-996 (1996).				
	BALLIN A, BERAR M, RUBINSTEIN U, KLETER Y, HERSHKOVITZ A. "Iron state in				
	female adolescents." AJDC, 146:803-805 (1992).				
	GRONER JA, HOLTZMAN NA, CHARNEY E, MELLITS ED. "A randomized trial of oral				
	iron on tests of short-term memory and attention span in young pregnant women." JAdolesc	1			
	Health Care, 7:44-48 (1986).				
	PRASAD AS. "Zinc: An overview." Nutrition, 11:93-99 (1995).				
	TOREN P, ELDAR S, SELA B-A, WOLMER L, WEITZ R, INBAR D, KOREN S, REISS A,				
	WEIZMAN R, LAOR N. "Zinc deficiency in attention-deficit hyperactivity disorder." Biol				
	Psychiatry, 40:1308-1310 (1996).				
	CONSTANTINIDIS J. "The hypothesis of zinc deficiency in the pathogenesis of neurofibrillary				
	tangles." Med Hypotheses, 3 5:319-323 (1991).				

Examiner	Date	
Signature	 Considered	

Form PT	O/SB/08A	 	,		Complete if Known	
l				Application Number	10/519,515	
			OSURE	Filing Date	December 7, 2004	
STATE	MENT B	Y APPL	LICANT	First Named Inventor	Kyl L. Smith	
(,,,,,	(use as many sheets as necessary)			Group Art Unit	1654	
(use a			ecessary)	Examiner Name	Not Yet Assigned	
Sheet	26	of	29	Attorney Docket Number	681132-2US	

	U.S. PATENT DOCUMENTS						
Exr Initials	U.S. Patent Document		Name of First Inventor of Cited Document	Date of Publication of			
	Number	Kind Code (if known)		Cited Document MM-YYYY			

-	FOREIGN PATENT DOCUMENTS							
Exr Initials	Country Code	Foreign Patent Docum Number	Kind Code (if known)	Name of Applicant of Cited Document	Date of Publication of Cited Document MM-YYYY	T ₁		
		-						

	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	1 =
Exr Initials	Include Name of first Author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), volume-issue number(s), page(s), date (in parentheses). If a book, also include publisher and city and/or county where published.	T ₁
	BEKAROGLU M, ASIAN Y, GEDIK Y, DEGER O, MOCAN H, ERDURAN E, KARAHAN	i.
	C. "Relationships between serum free fatty acids and zinc, and attention deficit hyperactivity	
	disorder: A research note." J Child Psychol Psychiat, 37:225-227 (1996).	
	PENLAND JG. "Quantitative analysis of EEG effects following experimental marginal	
	magnesium and boron deprivation." Mag Res, 8:341-358 (1995).	
	MOUNTOKALAKIS TD. "Effects of aging, chronic disease, and multiple supplements on	-
	magnesium requirements." Magnesium, 6:5-11 (1987).	
	FROZEL D, COPPEN A, MARKS V. "Plasma magnesium and calcium in depression." BrJ	
	Psychiat, 115:1375-1377 (1969).	
	NIELSEN FH. "The justification for providing dietary guidance for the nutritional intake of	İ
	boron." Biol Trace Element Res, 66:319-330 (1998).	<u> </u>
	HUNT CD, STOECKER BJ. "Deliberations and evaluations of the approaches, endpoints and	
	paradigms for boron, chromium and fluoride dietary recommendations." JNutr, 126:2441S-	
	2451S (1996).	
	PENLAND JG. "Dietary boron, brain function, and cognitive performance." Environ Health	1
	Perspect, 102(suppl 7):65-72 (1994).	
	TOLMAN EL, BARRIS E, BURNS M, PANSINI A, PARTRIDGE R "Effects of vanadium on	
	glucose metabolism in vitro." Life Sci, 25:1159-1164 (1979).	
	SHECHTER Y, KARLISH SJD. "Insulin-like stimulation of glucose oxidation in rat adipocytes	
	by vanadyl (IV) ions." <i>Nature</i> , 284:556-558 (1980).	
	CLAUSEN T, ANDERSEN TL, STUMP-JOHANSEN M, PETKOVA O. "The relationship	
	between the transport of glucose and cations across cell membranes in isolated tissues. XI. The	
	effect ofvanadate on 45Ca-efflux and sugar transport in adipose tissue and skeletal muscle."	
	Biochimica Biophysica Ada, 646:261-267 (1981).	
	CLARK AS, FAGAN JM, MITCH WE. "Selectivity of the insulin-like actions of vanadate on	
	glucose and protein metabolism in skeletal muscle." Biochem J, 232:273-276 (1985).	

Examiner	Date	
Signature	Considered	

Form PT	O/SB/08A			Complete if Known			
INFORMATION DISCLOSURE			Application Number	10/519,515			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Filing Date	December 7, 2004		
STATE	MENT B	Y APPL	LICANT	First Named Inventor	Kyl L. Smith		
f	(use as many sheets as necessary)			Group Art Unit	1654		
(use a			ecessary)	Examiner Name	Not Yet Assigned		
Sheet	27	of	29	Attorney Docket Number	681132-2US		

U.S. PATENT DOCUMENTS						
Exr Initials	U.S. Patent Document		Name of First Inventor of Cited Document	Date of Publication of		
	Number	Kind Code (if	1	Cited Document		
		known)		MM-YYYY		

	FOREIGN PATENT DOCUMENTS								
Exr Initials	Country Code	Foreign Patent Docum Number	Kind Code (if known)	Name of Applicant of Cited Document	Date of Publication of Cited Document MM-YYYY	T₁			
•									

	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Exr Initials	Include Name of first Author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), volume-issue number(s), page(s), date (in parentheses). If a book, also include publisher and city and/or county where published.	T ₁
	SEKAR N, KANTHASAMY A, WILLIAM S, SUBRAMANAIAN S, GOVINDASAMY S.	
	"Insulinic actions of vanadate in diabetic rats." Pharmacol Res, 22:207-217 (1990).	
	SAKURAI H, TSUCHIYA K, NUKATSUKA M, SOFIIE M, KAWADA J. "Insulin-like effect	
	of vanadyl ion on streptozotocin-induced diabetic rats." <i>J Endocrinol</i> , 126:451-459 (1990).	
	PANDEY SK, ANAND-SRIVASTAVA MB, SRIVASTAVA AK. "Vanadyl sulfte-stimulated	
	glucogen synthesis is associated with activation of phosphatidylinositol 3-kinase and is	
	independent of insulin receptor tyrosine phosphorylation." Biochemistry, 37:7006-7014 (1998).	
	COHEN N, HALBERSTAM M, SHLIMOVICH P, CHANG CJ, SHAMOON H, ROSETTI M.	
	"Oral vanadyl sulfate improves hepatic and peripheral insulin sensitivity in patients with non-	
	insulin-dependent diabetes mellitus." J Clin Invest, 95.2501-2509 (1995).	
	CASTRO J, MAQUEDANO A, OLIVE M. "Lipid synthesis in isolated rat hepatocytes:	
	Activation by insulin and vanadate and inhibition by ouabain." Biochem Intern, 9:413-420 (1984).	
	RODRIGUEZ-GIL JE, GOMEZ-FOIX AM, FILLAT C, BOSCH F, GUINOVART JJ.	
	"Activation by vanadate of glycolysis in hepatocytes from diabetic rats." <i>Diabetes</i> , 40:1355-1359 (1991).	
	STANLEY BG, KYRKOULI SE, LAMPERT S, LEIBOWITZ SF. "Neuropeptide Y chronically	
	injected into the hypothalamus: A powerful neurochemical inducer of hyperphagia and obesity."	
	Peptides, 7:1189-1192 (1986).	
	MORLEY JE, LEVINE AS, GOSNELL BA, KNEIP J, GRACE M. "Effect of neuropeptide Y	
	on ingestive behaviors in the rat." Am JPhysiol, 252:R599-R609 (1987).	
	BILLINGTON CJ, BRIGGS JE, GRACE M, LEVINE AS. "Effects of intracerebroventricular	
	injection of neuropeptide Y on energy metabolism." Am JPhysiol, 260:R321-R327 (1991).	

Examiner	Date	
Signature	Considered	

Form PT	O/SB/08A			Complete if Known			
INFORMATION DISCLOSURE				Application Number	10/519,515		
				Filing Date	December 7, 2004		
STATE	STATEMENT BY APPLICANT			First Named Inventor	Kyl L. Smith		
(,,,,,,,				Group Art Unit	1654		
(use as many sheets as necessary)		Examiner Name	Not Yet Assigned				
Sheet	28	of	29	Attorney Docket Number	681132-2US		

U.S. PATENT DOCUMENTS					
Exr Initials	U.S. Patent Document		Name of First Inventor of Cited Document	Date of Publication of	
	Number	Kind Code (if known)		Cited Document MM-YYYY	

		F	OREIGN PATE	NT DOCUMENTS		
Exr Initials	Country Code	Foreign Patent Documer Number	Kind Code (if known)	Name of Applicant of Cited Document	Date of Publication of Cited Document MM-YYYY	T ₁

	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Exr Initials	Include Name of first Author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), volume-issue number(s), page(s), date (in parentheses). If a book, also include publisher and city and/or county where published.	T ₁
	MALABU UH, DRYDEN S, MCCARTHY HD, KILPATRICK A, WILLIAMS G. "Effects of	
	chronic vanadate administration in the STZ-induced diabetic rat. The antihyperglycemic action of vanadate is attributable entirely to its suppression of feeding." <i>Diabetes</i> , 43:9-15 (1994).	
		+
	BENTON D, COOK R. "Selenium supplementation improves mood in a double-blind crossover trial." <i>Psychopharmacol</i> , 102:549-550 (1990).	
	BENDICH A. "The potential for dietary supplements to reduce premenstrual syndrome (PMS) symptoms." J Am Coll Nutr, 19:3-12 (2000).	
	THYS-JACOBS S. "Micronutrients and the premenstrual syndrome: The case for calcium." J	
	Am Coll Nutr, 19:220-227 (2000).	
	THYS-JACOBS S, CECCARELLI S, BIERMANA, WEISMAN H, COHEN M-A, ALVIR J.	1
	"Calcium supplementation in premenstrual syndrome: A randomized crossover trial." J Gen	
_	Intern Med, 4:183-189 (1989).	╂—
	THYS-JACOBS S, STARKEY P, BERNSTEIN D, TIAN J. "Calcium carbonate and the	
	premenstrual syndrome: Effects on premenstrual and menstrual symptoms." Am J Obstet	
	Gynecol, 179:444-452 (1998).	<u> </u>
	PENLAND JG, JOHNSON PE. "Dietary calcium and manganese effects on menstrual cycle	
	symptoms." Am J Obstet Gynecol, 168:1417-1423 (1993).	╁
	FACCHINETTI F, BORELLA P, SANCES G, FIORONI L, NAPPI R, GENAZZANI AR.	
	"Oral magnesium successfully relieves premenstrual mood changes." Obstet Gynecol, 78:177-181	
	(1991).	_
	FACCHINETTI F, SANCES G, BORELLA P, GENAZZANI AR, NAPPI G. "Magnesium	
	prophylaxis pf menstrual migraine: Effects on intracellular magnesium." Headache, 31:298-301	
	(1991).	

Examiner	Date	
Signature	Considered	

Form PT	O/SB/08/	\			Complete if Known	
.0.4				Application Number	10/519,515	
INFORMATION DISCLOSURE				Filing Date	December 7, 2004	
STATE	STATEMENT BY APPLICANT			First Named Inventor	Kyl L. Smith	
(,,,,,			\	Group Art Unit	1654	
(use a	as many s	sheets as n	ecessary)	Examiner Name	Not Yet Assigned	
Sheet	29	of	29	Attorney Docket Number	681132-2US	

		U.S	. PATENT DOCUMENTS	
Exr Initials	U.S. Patent Document		Name of First Inventor of Cited Document	Date of Publication of
	Number	Kind Code (if known)		Cited Document MM-YYYY

			FOREIGN PATE	NT DOCUMENTS		
Exr Initials	0	Foreign Patent Docum		Name of Applicant of Cited Document	Date of Publication of	T ₁
EXI IIIIIIIII	Country Code	Number	Kind Code (if known)	Name of Applicant of Cited Document	Cited Document	
			· · · · · · · · · · · · · · · · · · ·		MM-YYYY	
	ll					<u> </u>

	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Exr Initials	Include Name of first Author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), volume-issue number(s), page(s), date (in parentheses). If a book, also include publisher and city and/or county where published.	T ₁
	DE SOUZA MC, WALKER AF, ROBINSON PA, BOLLAND K. "A synergistic effect of a daily supplement for 1 month of 200 mg magnesium plus 50 mg vitamin B6 for the relief of	
	anxiety-related premenstrual symptoms: A randomized, double-blind, crossover study." <i>J Women's Health & Gender-Based Med</i> , 9:131-139 (2000).	
	BENTON D, ROBERTS G. "Effect of vitamin and mineral supplementation on intelligence of a sample of schoolchildren." <i>Lawcef</i> , 1:140-143 (1988).	
	SCHOENTHALLER SJ, BIER ID. "Vitamin-mineral intake and intelligence: A macrolevel analysis of randomized controlled trials." <i>J Alternative Complementary Med</i> , 5:125-134 (1999).	

Examiner	Date
Signature	Considered